apyrase and Carcinoma--Squamous-Cell

apyrase has been researched along with Carcinoma--Squamous-Cell* in 9 studies

Other Studies

9 other study(ies) available for apyrase and Carcinoma--Squamous-Cell

ArticleYear
ENTPD1 (CD39) Expression Inhibits UVR-Induced DNA Damage Repair through Purinergic Signaling and Is Associated with Metastasis in Human Cutaneous Squamous Cell Carcinoma.
    The Journal of investigative dermatology, 2021, Volume: 141, Issue:10

    UVR and immunosuppression are major risk factors for cutaneous squamous cell carcinoma (cSCC). Regulatory T cells promote cSCC carcinogenesis, and in other solid tumors, infiltrating regulatory T cells and CD8

    Topics: Adenosine; Apyrase; Carcinoma, Squamous Cell; DNA Damage; DNA Repair; Forkhead Transcription Factors; Humans; Interleukin-27; Memory T Cells; Neoplasm Metastasis; Programmed Cell Death 1 Receptor; Skin Neoplasms; Ultraviolet Rays

2021
CD39 Identifies the CD4
    Cancer immunology research, 2020, Volume: 8, Issue:10

    The accumulation of tumor-specific CD4

    Topics: Apyrase; Carcinoma, Squamous Cell; CD4-Positive T-Lymphocytes; Humans; Neoplasms; T-Lymphocytes

2020
Ectonucleotidase CD39 expression in regional metastases in head and neck cancer.
    Acta oto-laryngologica, 2018, Volume: 138, Issue:4

    CD39 is the rate-limiting enzyme in the generation of immunosuppressive adenosine and its expression and activity are significant in tumor progression. Squamous cell carcinoma of the head and neck (HNSCC) shows an overall poor prognosis due to high local recurrence rates and early metastatic spread.. Primary tumor specimens and lymph node specimens harvested during neck dissection of 65 patients with a diagnosis of HNSCC were subjected to immunohistochemical and H-score analysis of CD39 expression. Demographics, histopathology and subsequent outcome were analyzed.. The primary cancer was squamous cell carcinoma in all patients (male/female 55:10). H-score for CD39 expression in the primary lesion and metastatic lymph nodes was significantly higher in advanced compared to early stages with no significant differences among different tumor locations. High intratumoral and intrametastatic CD39 expression was associated with an inferior patients' overall survival at a mean follow-up of 83.4 months (6-204 months).. CD39 expression in HNSCC correlated positively with tumor stage and appears to predict poor prognosis. Therefore, CD39 expression in primary lesions and metastatic lymph nodes seems to identify patients at high risk in HNSCC of all tumor sites. Immunotherapeutic approaches targeting CD39 might be promising for this patient population.

    Topics: Aged; Apyrase; Carcinoma, Squamous Cell; Female; Germany; Head and Neck Neoplasms; Humans; Lymph Nodes; Lymphatic Metastasis; Male; Middle Aged; Retrospective Studies

2018
Co-expression of CD39 and CD103 identifies tumor-reactive CD8 T cells in human solid tumors.
    Nature communications, 2018, 07-13, Volume: 9, Issue:1

    Identifying tumor antigen-specific T cells from cancer patients has important implications for immunotherapy diagnostics and therapeutics. Here, we show that CD103

    Topics: Adenocarcinoma of Lung; Antigens, CD; Apyrase; Carcinoma, Squamous Cell; CD8 Antigens; CD8-Positive T-Lymphocytes; Female; Humans; Immunophenotyping; Integrin alpha Chains; Lymphocytes, Tumor-Infiltrating; Male; Melanoma; Ovarian Neoplasms; Receptors, Antigen, T-Cell, alpha-beta; Squamous Cell Carcinoma of Head and Neck; Survival Analysis; Transcriptome

2018
Intratumoral regulatory T cells upregulate immunosuppressive molecules in head and neck cancer patients.
    British journal of cancer, 2013, Nov-12, Volume: 109, Issue:10

    Although regulatory T cells (Treg) are highly enriched in human tumours compared with peripheral blood, expression of the immune-checkpoint receptors, immunosuppressive molecules and function of Treg in these two sites remains undefined.. Tumour-infiltrating lymphocytes and peripheral blood lymphocytes were isolated from a cohort of head and neck squamous cell carcinoma (HNSCC) patients. The immunosuppressive phenotypes and function of intratumoral Treg were compared with those of peripheral blood Treg.. The frequency of immune-checkpoint receptor-positive cells was higher on intratumoral FOXP3(+)CD25(hi) Treg compared with circulating Treg (CTLA-4, P=0.002; TIM-3, P=0.002 and PD-1, P=0.002). Immunosuppressive effector molecules, LAP and ectonucleotidase CD39 were also upregulated on intratumoral FOXP3(+) Treg (P=0.002 and P=0.004, respectively). CTLA-4 and CD39 were co-expressed on the majority of intratumoral FOXP3(+)CD4(+) Treg, suggesting that these molecules have a key role in regulatory functions of these cells in situ. Notably, intratumoral Treg exhibited more potently immunosuppressive activity than circulating Treg.. These results indicate that intratumoral Treg are more immunosuppressive than circulating Treg and CTLA-4 and CD39 expressed can be potential target molecules to inhibit suppressive activities of intratumoral Treg in situ.

    Topics: Adult; Aged; Aged, 80 and over; Antigens, CD; Apyrase; Carcinoma, Squamous Cell; CTLA-4 Antigen; Cytokines; Female; Head and Neck Neoplasms; Humans; Immune Tolerance; Immunosuppressive Agents; Lymphocytes, Tumor-Infiltrating; Male; Middle Aged; Squamous Cell Carcinoma of Head and Neck; T-Lymphocytes, Regulatory

2013
Adenosine and prostaglandin E2 cooperate in the suppression of immune responses mediated by adaptive regulatory T cells.
    The Journal of biological chemistry, 2010, Sep-03, Volume: 285, Issue:36

    Adaptive regulatory T cells (Tr1) are induced in the periphery upon encountering cognate antigens. In cancer, their frequency is increased; however, Tr1-mediated suppression mechanisms are not yet defined. Here, we evaluate the simultaneous involvement of ectonucleotidases (CD39/CD73) and cyclooxygenase 2 (COX-2) in Tr1-mediated suppression. Human Tr1 cells were generated from peripheral blood mononuclear cell-derived, sorted CD4(+)CD25(-) T cells and incubated with autologous immature dendritic cells, irradiated COX-2(+) or COX-2(-) tumor cells, and IL-2, IL-10, and IL-15 (each at 10-15 IU/ml) for 10 days as described (Bergmann, C., Strauss, L., Zeidler, R., Lang, S., and Whiteside, T. L. (2007) Cancer Immunol. Immunother. 56, 1429-1442). Tr1 were phenotyped by multicolor flow cytometry, and suppression of proliferating responder cells was assessed in carboxyfluorescein diacetate succinimidyl ester-based assays. ATP hydrolysis was measured using a luciferase detection assay, and levels of adenosine or prostaglandin E(2) (PGE(2)) in cell supernatants were analyzed by mass spectrometry or ELISA, respectively. Intracellular cAMP levels were measured by enzyme immunoassay. The COX-2(+) tumor induced a greater number of Tr1 than COX-2(-) tumor (p < 0.05). Tr1 induced by COX-2(+) tumor were more suppressive, hydrolyzed more exogenous ATP (p < 0.05), and produced higher levels of adenosine and PGE(2) (p < 0.05) than Tr1 induced by COX-2(-) tumor. Inhibitors of ectonucleotidase activity, A(2A) and EP(2) receptor antagonists, or an inhibitor of the PKA type I decreased Tr1-mediated suppression (p < 0.05), whereas rolipram, a PDE(4) inhibitor, increased the intracellular cAMP level in responder cells and their susceptibility to Tr1-mediated suppression. Tr1 present in tumors or the peripheral blood of head and neck squamous cell carcinoma patients co-expressed COX-2, CD39, and CD73. A concomitant inhibition of PGE(2) and adenosine via the common intracellular cAMP pathway might be a novel approach for improving results of immune therapies for cancer.

    Topics: 5'-Nucleotidase; Adaptive Immunity; Adenosine; Amino Acids, Cyclic; Antigens, CD; Apyrase; Carcinoma, Squamous Cell; Cell Line, Tumor; Cyclooxygenase 2; Dinoprostone; Down-Regulation; Gene Expression Regulation, Neoplastic; Head and Neck Neoplasms; Humans; Immune Tolerance; Intracellular Space; Signal Transduction; T-Lymphocyte Subsets; T-Lymphocytes, Regulatory

2010
Isolation of functional human regulatory T cells (Treg) from the peripheral blood based on the CD39 expression.
    Journal of immunological methods, 2009, Jul-31, Volume: 346, Issue:1-2

    Human regulatory T cells (Treg) have been variously defined as CD4(+)CD25(+), CD4(+)CD25(high) or CD4(+)CD25(high)FOXP3(+) cells which are responsible for maintaining peripheral tolerance. Their isolation from human peripheral blood or tissues depends on the expression level of CD25(IL-2Ralpha) - a surface marker which is also expressed on activated effector helper T cells. CD39, a cell surface associated ectonucleotidase, can be used to purify Treg with strong suppressor functions. The CD4(+)CD39(+) T cells catalyze cleavage of adenosine triphosphate (ATP) to adenosine monophosphate (AMP), which is then further cleaved to adenosine. CD4(+)CD39(+) T cells largely overlap with CD4(+)CD25(high)FOXP3(+) but not CD4(+)CD25(+) T cell subset, and mediate equally potent immune suppression. Thus, CD39 surface marker can be successfully used for routine isolation of functionally-active human Treg from the peripheral blood of healthy donors or patients with cancer for studies of their role in health and disease.

    Topics: Adult; Antigens, CD; Apyrase; Carcinoma, Squamous Cell; Case-Control Studies; Cells, Cultured; Female; Flow Cytometry; Forkhead Transcription Factors; Head and Neck Neoplasms; Humans; Immunomagnetic Separation; Immunophenotyping; Interleukin-2 Receptor alpha Subunit; Male; Middle Aged; Reproducibility of Results; T-Lymphocytes, Regulatory; Young Adult

2009
Increased ectonucleotidase expression and activity in regulatory T cells of patients with head and neck cancer.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2009, Oct-15, Volume: 15, Issue:20

    Regulatory T cell (Treg) frequency and activity are increased in cancer patients and play a major role in tumor escape. Although disease progression is favored by the presence of Treg, mechanisms used by Treg to suppress antitumor immunity are unknown. The ectonucleotidases CD39 and CD73 are expressed in Treg and convert ATP into immunosuppressive adenosine. In this study, the involvement of the adenosinergic pathway in Treg-mediated suppression in head and neck squamous cell carcinoma (HNSCC) patients was evaluated.. HNSCC patients with an active disease (n = 19) and patients with no evident disease after therapy (n = 14) were studied. Ectonucleotidase expression on CD4(+) T cells and CD4(+)CD25(high) Treg was evaluated by flow cytometry and compared with normal controls. Ectonucleotidase activity was also compared within these three groups. The data were analyzed for associations of ectonucleotidase expression/function with disease stage.. The percentages and expression levels of CD39 and CD73 in CD4(+) T cells and Treg were greater in HNSCC than in normal controls and highest in patients with no evident disease. Patients' Treg hydrolyzed ATP at higher rates and produced higher levels of adenosine than normal controls' Treg. The increased frequency and enzymatic activity of CD4(+)CD39(+) cells corresponded to increased adenosine-mediated suppression of effector T cells, which was partly inhibited by ARL67156, an ectonucleotidase inhibitor, and by ZM241385, a selective A(2a)/A(2b) receptor antagonist.. CD39(+) Treg frequency and adenosine-mediated suppression are significantly increased in HNSCC patients. The adenosinergic pathway is involved in Treg-mediated immunosuppression in cancer and its attenuation could be a promising immunotherapeutic strategy for patients with HNSCC.

    Topics: 5'-Nucleotidase; Adenosine Triphosphate; Adult; Aged; Antigens, CD; Apyrase; Carcinoma, Squamous Cell; CD4-Positive T-Lymphocytes; Female; Head and Neck Neoplasms; Humans; Immunosuppression Therapy; Male; Middle Aged; N-Glycosyl Hydrolases; T-Lymphocytes, Regulatory

2009
Nucleotide metabolizing ectoenzymes are upregulated in A431 cells periodically treated with cytostatic ATP leading to partial resistance without preventing apoptosis.
    Biochimica et biophysica acta, 1998, Sep-16, Volume: 1404, Issue:3

    Extracellular ATP, when added as a single dose at concentrations higher than 0.1 mM to the culture medium, was growth inhibitory or even cytotoxic for human epidermoid carcinoma cells (A431). Adenosine at the same concentrations was much less potent. The molecular mechanism underlying the inhibitory effect of extracellular ATP has been investigated. The cytostatic as well as the cytotoxic effects of ATP could be prevented by supplying uridine as a pyrimidine source and, alternatively, by simultaneous addition of dipyridamole, which inhibits the uptake of adenosine. The data suggest that the long-term production and continuous uptake of adenosine, which is enzymatically generated from the ATP in the medium, led to an intracellular nucleotide imbalance with pyrimidine starvation. This triggered suicidal processes ending up in apoptosis of the cells. The tumor cells have been adapted to extracellular ATP with the aim to obtain cells which are more resistant to ATP. Therefore, growing cells were periodically treated with extracellular ATP. These cells were characterized by an enlargement of cell size, a decreased proliferation rate, and a reduced but not abolished sensitivity to cytostatic and cytotoxic ATP doses. The calcium response of adapted cells was shortened. The nucleotide hydrolyzing ectoenzyme activities (ecto-ATPase, ecto-ADPase, ecto-AMPase, ecto-Ap4Aase) were simultaneously upregulated. All phenotypic alterations of the adapted cells disappeared after cultivation for several generations in the absence of extracellular ATP. Considering ATP as a potential chemotherapeutic agent the adaptive phenomena of treated cells might be important.

    Topics: Adenosine Triphosphatases; Adenosine Triphosphate; Apoptosis; Apyrase; Calcium; Carcinoma, Squamous Cell; Cell Division; Cell Membrane; Cell Survival; Culture Media; Dinucleoside Phosphates; DNA Fragmentation; Glutathione; Humans; Hydrolysis; L-Lactate Dehydrogenase; Nucleotidases; Tumor Cells, Cultured; Up-Regulation

1998